#PAGE_PARAMS# #ADS_HEAD_SCRIPTS# #MICRODATA#
CS
proLékaře.cz / Journals / Internal Medicine / 2018 - 12

Combined lipid-lowering therapy

Czech version

Authors: David Karásek
Authors‘ workplace: III. interní klinika – nefrologická, revmatologická a endokrinologická LF UP a FN Olomouc
Published in: Vnitř Lék 2018; 64(12): 1177-1184
Category:

Overview

Dyslipidemia belongs to the main risk factors for atherosclerosis. To achieve current blood lipid targets, it is often necessary to use intensive hypolipidemic therapy including a combination of individual hypolipidemic drugs. In terms of cardiovascular risk reduction, it is important that the patient is treated with the highest tolerated dose of statin. In the next step, we decide to co-administer ezetimibe and/or fibrate, and for high-risk patients an additional treatment with proprotein convertase subtilisin kexin 9 inhibitors should be considered. The manuscript provides an overview of the individual combinations effectiveness to influence lipid spectrum and the incidence of cardiovascular diseases.

Key words:

cardiovascular disease – dyslipidemia – ezetimibe – fibrates – PCSK9 inhibitors – statins

Sources
  1. Kearney PM, Blackwell L, Collins R et al. [Cholesterol Treatment Trialists‘ (CTT) Collaborators]. Efficacy of cholesterol-lowering therapy in 18,686 people with diabetes in 14 randomised trials of statins: a meta-analysis. Lancet 2008; 371(9607): 117–125. Dostupné z DOI: <http://dx.doi.org/10.1016/S0140–6736(08)60104-X>.
  2. Baigent C, Blackwell L, Emberson J et al. [Cholesterol Treatment Trialists’ (CTT) Collaboration]. Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170,000 participants in 26 randomised trials. Lancet 2010; 376(9753): 1670–1681. Dostupné z DOI: <http://dx.doi.org/10.1016/S0140–6736(10)61350–5>.
  3. Ference BA, Ginsberg HN, Graham I et al. Low-density lipoproteins cause atherosclerotic cardiovascular disease. 1. Evidence from genetic, epidemiologic, and clinical studies. A consensus statement from the European Atherosclerosis Society Consensus Panel. Eur Heart J 2017; 38(32): 2459–2472. Dostupné z DOI: <http://dx.doi.org/10.1093/eurheartj/ehx144>.
  4. Catapano AL, Graham I, De Backer G et al. [ESC Scientific Document Group]. 2016 ESC/EAS Guidelines for the Management of Dyslipidaemias. Eur Heart J 2016; 37(39): 2999–3058.Dostupné z DOI: <http://dx.doi.org/10.1093/eurheartj/ehw272>.
  5. Stone NJ, Robinson JG, Lichtenstein AH et al. [American College of Cardiology/American Heart Association Task Force on Practice Guidelines]. 2013 ACC/AHA guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk in adults: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol 2014; 63(25 Pt B): 2889–2934. Dostupné z DOI: <http://dx.doi.org/10.1016/j.jacc.2013.11.002>. Erratum in J Am Coll Cardiol. 2015; 66(24): 2812. J Am Coll Cardiol 2014; 63(25 Pt B): 3024–3025.
  6. Karalis DG, Victor B, Ahedor L et al. Use of Lipid-Lowering Medications and the Likelihood of Achieving Optimal LDL-Cholesterol Goals in Coronary Artery Disease Patients. Cholesterol 2012; 2012: 861924. Dostupné z DOI: <http://dx.doi.org/10.1155/2012/861924>.
  7. Vrablík M. Farmakoterapie dyslipidemie. 2. ed. Maxdorf: Praha 2016. ISBN 978–80–7345–503–3 (brož). ISBN 978–80–7345–504–0 (spec ed).
  8. Karásek D. Diabetická dyslipidemie. Maxdorf: Praha 2018. ISBN 978–80–7345–556–9.
  9. Bays HE, Moore PB, Drehobl MA et al. Ezetimibe Study Group. Effectiveness and tolerability of ezetimibe in patients with primary hypercholesterolemia: pooled analysis of two phase II studies. Clin Ther 2001; 23(8): 1209–1230. Erratum in Clin Ther 2001; 23(9): 1601.
  10. Pandor A, Ara RM, Tumur I et al. Ezetimibe monotherapy for cholesterol lowering in 2,722 people: systematic review and meta-analysis of randomized controlled trials. J Intern Med 2009; 265(5): 568–580. Dostupné z DOI: <http://dx.doi.org/10.1111/j.1365–2796.2008.02062.x>.
  11. Catapano A, Brady WE, King TR et al. Lipid altering-efficacy of ezetimibe co-administered with simvastatin compared with rosuvastatin: a meta-analysis of pooled data from 14 clinical trials. Curr Med Res Opin 2005; 21(7): 1123–1130. Dostupné z DOI: <http://dx.doi.org/10.1185/030079905X50642>.
  12. Ballantyne CM, Houri J, Notarbartolo A et al. Ezetimibe Study Group. Effect of ezetimibem coadministered with atorvastatin in 628 patients with primary hypercholesterolemia: a prospective, randomized, double-blind trial. Circulation 2003; 107(19): 2409–2415. Dostupné z DOI: <http://dx.doi.org/10.1161/01.CIR.0000068312.21969.C8>.
  13. Conard SE, Bays HE, Leiter LA et al. Efficacy and safety of ezetimibe added on to atorvastatin (20 mg) versus uptitration of atorvastatin (to 40 mg) in hypercholesterolemic patients at moderately high risk for coronary heart disease. Am J Cardiol 2008; 102(11): 1489–1494. Dostupné z DOI: <http://dx.doi.org/10.1016/j.amjcard.2008.09.075>.
  14. Leiter LA, Bays H, Conard S et al. Efficacy and safety of ezetimibe added on to atorvastatin (40 mg) compared with uptitration of atorvastatin (to 80 mg) in hypercholesterolemic patients at high risk of coronary heart disease. Am J Cardiol 2008; 102(11): 1495–1501. Dostupné z DOI: <http://dx.doi.org/10.1016/j.amjcard.2008.09.076>.
  15. Stein E, Stender S, Mata P et al. Ezetimibe Study Group. Achieving lipoprotein goals in patients at high risk with severe hypercholesterolemia: efficacy and safety of ezetimibe co-administered with atorvastatin. Am Heart J 2004; 148(3): 447–455. Dostupné z DOI: <http://dx.doi.org/10.1016/j.ahj.2004.03.052>.
  16. Zieve F, Wenger NK, Ben-Yehuda O et al. Safety and efficacy of ezetimibe added to atorvastatin versus up titration of atorvastatin to 40 mg in patients > or = 65 years of age (from the ZETia in the ELDerly [ZETELD] study). Am J Cardiol 2010; 105(5): 656–663. Dostupné z DOI: <http://dx.doi.org/10.1016/j.amjcard.2009.10.029>.
  17. Bays HE, Averna M, Majul C et al. Efficacy and safety of ezetimibe addend to atorvastatin versus atorvastatin uptitration or switching to rosuvastatin in patients with primary hypercholesterolemia. Am J Cardiol 2013; 112(12): 1885–1895. Dostupné z DOI: <http://dx.doi.org/10.1016/j.amjcard.2013.08.031>.
  18. Ballantyne CM, Hoogeveen RC, Raya JL et al. [GRAVITY Study Investigators]. Efficacy, safety and effect on biomarkers related to cholesterol and lipoprotein metabolism of rosuvastatin 10 or 20 mg plus ezetimibe 10 mg vs. simvastatin 40 or 80 mg plus ezetimibe 10 mg in high-risk patients: Results of the GRAVITY randomized study. Atherosclerosis 2014; 232(1): 86–93. Dostupné z DOI: <http://dx.doi.org/10.1016/j.atherosclerosis.2013.10.022>.
  19. Ballantyne CM, Weiss R, Moccetti T et al. [EXPLORER Study Investigators]. Efficacy and safety of rosuvastatin 40 mg alone or in combination with ezetimibe in patients at high risk of cardiovascular disease (results from the EXPLORER study). Am J Cardiol 2007; 99(5): 673–680. Dostupné z DOI: <http://dx.doi.org/10.1016/j.amjcard.2006.10.022>.
  20. Gagné C, Gaudet D, Bruckert E et al. [Ezetimibe Study Group]. Efficacy and safety of ezetimibem coadministered with atorvastatin or simvastatin in patients with homozygous familial hypercholesterolemia. Circulation 2002; 105(21): 2469–2475.
  21. Denke M, Pearson T, McBride P et al. Ezetimibe added to ongoing statin therapy improves LDL-C goal attainment and lipid profile in patients with diabetes or metabolic syndrome. Diab Vasc Dis Res 2006; 3(2): 93–102. Dostupné z DOI: <http://dx.doi.org/10.3132/dvdr.2006.020>.
  22. Baigent C, Landray MJ, Reith C et al. [SHARP Investigators]. The effects of lowering LDL cholesterol with simvastatin plus ezetimibe in patients with chronic kidney disease (Study of Heart and Renal Protection): a randomised placebo-controlled trial. Lancet 2011; 377(9784): 2181–2192. Dostupné z DOI: <http://dx.doi.org/10.1016/S0140–6736(11)60739–3>.
  23. Rossebø AB, Pedersen TR, Boman K et al. [SEAS Investigators]. Intensive lipid lowering with simvastatin and ezetimibe in aortic stenosis. N Engl J Med 2008; 359(13): 1343–1356. Dostupné z DOI: <http://dx.doi.org/10.1056/NEJMoa0804602>.
  24. Cannon CP, Blazing MA, Giugliano RP et al. [IMPROVE-IT Investigators]. Ezetimibe Added to Statin Therapy after Acute Coronary Syndromes. N Engl J Med 2015; 372(25): 2387–2397. Dostupné z DOI: <http://dx.doi.org/10.1056/NEJMoa1410489>.
  25. Giugliano RP, Cannon CP, Blazing MA et al. [IMPROVE-IT (Improved Reduction of Outcomes: Vytorin Efficacy International Trial) Investigators]. Benefit of Adding Ezetimibe to Statin Therapy on Cardiovascular Outcomes and Safety in Patients With Versus Without Diabetes Mellitus: Results From IMPROVE-IT (Improved Reduction of Outcomes: Vytorin Efficacy International Trial). Circulation 2018; 137(15): 1571–1582. Dostupné z DOI: <http://dx.doi.org/10.1161/CIRCULATIONAHA.117.030950>.
  26. Eisen A, Cannon CP, Blazing MA et al. [[IMPROVE-IT (IMProved Reduction of Outcomes: Vytorin Efficacy International Trial) Investigators]. The benefit of adding ezetimibe to statin therapy in patients with prior coronary artery bypass graft surgery and acute coronary syndrome in the IMPROVE-IT trial. Eur Heart J 2016; 37(48): 3576–3584. Dostupné z DOI: <http://dx.doi.org/10.1093/eurheartj/ehw377>.
  27. Tsujita K, Sugiyama S, Sumida H et al. [PRECISE–IVUS Investigators]. Impact of Dual Lipid-Lowering Strategy With Ezetimibe and Atorvastatin on Coronary Plaque Regression in Patients With Percutaneous Coronary Intervention: The Multicenter Randomized Controlled PRECISE-IVUS Trial. J Am Coll Cardiol 2015; 66(5): 495–507. Dostupné z DOI: <http://dx.doi.org/10.1016/j.jacc.2015.05.065>.
  28. Tsujita K, Yamanaga K, Komura N et al. [PRECISE-IVUS Investigators]. Lipid profile associated with coronary plaque regression in patients with acute coronary syndrome: Subanalysis of PRECISE-IVUS trial. Atherosclerosis 2016; 251: 367–372. Dostupné z DOI: <http://dx.doi.org/10.1016/j.atherosclerosis.2016.05.025>.
  29. Masuda J, Tanigawa T, Yamada T et al. Effect of combination therapy of ezetimibe and rosuvastatin on regression of coronary atherosclerosis in patients with coronary artery disease. Int Heart J 2015; 56(3): 278–285. Dostupné z DOI: <http://dx.doi.org/10.1536/ihj.14–311>.
  30. Luo P, Wang L, Zhu H et al. Impact of Atorvastatin Combined with Ezetimibe for the Treatment of Carotid Atherosclerosis in Patients with Coronary Heart Disease. Acta Cardiol Sin 2016; 32(5): 578–585.
  31. Wang J, Ai XB, Wang F et al. Efficacy of ezetimibe combined with atorvastatin in the treatment of carotid artery plaque in patients with type 2 diabetes mellitus complicated with coronary heart disease. Int Angiol 2017; 36(5): 467–473. Dostupné z DOI: <http://dx.doi.org/10.23736/S0392–9590.17.03818–4>.
  32. Moutzouri E, Kei A, Elisaf MS et al. Management of dyslipidemias with fibrates, alone and in combination with statins: role of delayed-release fenofibric acid. Vasc Health Risk Manag 2010; 6: 525–539.
  33. Zheng S, Li YX, Han TT et al. Systematic review and meta-analysis of Statins-Fibrates therapy in diabetic dyslipidemia patients. World J Meta-Anal 2014; 2(4): 194–203. Dostupné z DOI: <http://dx.doi.org/10.13105/wjma.v2.i4.194>.
  34. Ginsberg HN, Elam MB, Lovato LC et al. [ACCORD Study Group]. Effects of combination lipid therapy in type 2 diabetes mellitus. N Engl J Med 2010; 362(7): 1563–1574. Dostupné z DOI: <http://dx.doi.org/10.1056/NEJMoa1001282>. Erratum in N Engl J Med 2010; 362(18): 1748.
  35. Elam M, Lovato L, Ginsberg H. The ACCORD-Lipid study: implications for treatment of dyslipidemia in Type 2 diabetes mellitus. Clin Lipidol 2011; 6(1): 9–20. Dostupné z DOI: <http://dx.doi.org/10.2217/clp.10.84>.
  36. Elam MB, Ginsberg HN, Lovato LC et al. [ACCORDION Study Investigators]. Association of Fenofibrate Therapy With Long-term Cardiovascular Risk in Statin-Treated Patients With Type 2 Diabetes. JAMA Cardiol 2017; 2(4): 370–380. Dostupné z DOI: <http://dx.doi.org/10.1001/jamacardio.2016.4828>.
  37. Bruckert E, Labreuche J, Deplanque D et al. Fibrates effect on cardiovascular risk is greater in patients with high triglyceride levels or atherogenic dyslipidemia profile: a systematic review and meta-analysis. J Cardiovasc Pharmacol 2011; 57(2): 267–272. Dostupné z DOI: <http://dx.doi.org/10.1097/FJC.0b013e318202709f>.
  38. Lee M, Saver JL, Towfighi A et al. Efficacy of fibrates for cardiovascular risk reduction in persons with atherogenic dyslipidemia: a meta-analysis. Atherosclerosis 2011; 217(2): 492–498. Dostupné z DOI: <http://dx.doi.org/10.1016/j.atherosclerosis.2011.04.020>.
  39. Davis TM, Ting R, Best JD et al. Fenofibrate Intervention and Event Lowering in Diabetes Study investigators. Effects of fenofibrate on renal function in patients with type 2 diabetes mellitus: the Fenofibrate Intervention and Event Lowering in Diabetes (FIELD) Study. Diabetologia 2011; 54(2): 280–290. Dostupné z DOI: <http://dx.doi.org/10.1007/s00125–010–1951–1>.
  40. Keech AC, Mitchell P, Summanen PA et al. ]FIELD study investigators]. Effect of fenofibrate on the need for laser treatment for diabetic retinopathy (FIELD study): a randomised controlled trial. Lancet 2007; 370(9600): 1687–1697. Dostupné z DOI: <http://dx.doi.org/10.1016/S0140–6736(07)61607–9>.
  41. Rajamani K, Colman PG, Li LP et al. [FIELD study investigators]. Effect of fenofibrate on amputation events in people with type 2 diabetes mellitus (FIELD study): a prespecified analysis of a randomised controlled trial. Lancet 2009; 373(9677): 1780–1788. Dostupné z DOI: <http://dx.doi.org/10.1016/S0140–6736(09)60698-X>.
  42. Chew EY, Ambrosius WT, Davis MD et al. [ACCORD Study Group; ACCORD Eye Study Group]. Effects of medical therapies on retinopathy progression in type 2 diabetes. N Engl J Med 2010; 363(3): 233–244. Dostupné z DOI: <http://dx.doi.org/10.1056/NEJMoa1001288>. Erratum in N Engl J Med 2011; 364(2): 190. N Engl J Med 2012; 367(25): 2458.
  43. Karásek D, Vaverková H. Diabetická dyslipidemie a mikrovaskulární komplikace diabetu. Vnitř Lék 2018; 64(1): 17–24.
  44. Farnier M, Freeman MW, Macdonell G et al. [Ezetimibe Study Group]. Efficacy and safety of the coadministration of ezetimibe with fenofibrate in patients with mixed hyperlipidaemia. Eur Heart J 2005; 26(9): 897–905. Dostupné z DOI: <http://dx.doi.org/10.1093/eurheartj/ehi231>.
  45. McKenney JM, Farnier M, Lo KW et al. Safety and efficacy of long-term co-administration of fenofibrate and ezetimibe in patients with mixed hyperlipidemia. J Am Coll Cardiol 2006; 47(8): 1584–1587. Dostupné z DOI: <http://dx.doi.org/10.1016/j.jacc.2005.11.072>.
  46. Shinnakasu A, Yamamoto K, Kurano M et al. The Combination Therapy of Fenofibrate and Ezetimibe Improved Lipid Profile and Vascular Function Compared with Statins in Patients with Type 2 Diabetes. J Atheroscler Thromb 2017; 24(7): 735–748. Dostupné z DOI: <http://dx.doi.org/10.5551/jat.39446>.
  47. Kumar SS, Lahey KA, Day A et al. Comparison of the efficacy of administering a combination of ezetimibe plus fenofibrate versus atorvastatin monotherapy in the treatment of dyslipidemia. Lipids Health Dis 2009; 8: 56. Dostupné z DOI: <http://dx.doi.org/10.1186/1476–511X-8–56>.
  48. Nobecourt E, Cariou B, Lambert G et al. Severe decrease in high-density lipoprotein cholesterol with the combination of fibrates and ezetimibe: A case series. J Clin Lipidol 2017; 11(1): 289–293. Dostupné z DOI: <http://dx.doi.org/10.1016/j.jacl.2016.10.012>.
  49. Farnier M, Retterstøl K, Steinmetz A et al. Comparative efficacy and safety of fenofibrate/pravastatin plus ezetimibe triple therapy and simvastatin/ezetimibe dual therapy in type 2 diabetic patients with mixed hyperlipidaemia and cardiovascular disease. Diab Vasc Dis Res 2012; 9(3): 205–215. Dostupné z DOI: <http://dx.doi.org/10.1177/1479164111430715>.
  50. Jones PH, Goldberg AC, Knapp HR et al. Efficacy and safety of fenofibric acid in combination with atorvastatin and ezetimibe in patients with mixed dyslipidemia. Am Heart J 2010; 160(4): 759–766. Dostupné z DOI: <http://dx.doi.org/10.1016/j.ahj.2010.06.045>.
  51. Češka R, Táborský M, Vrablík M. Společné stanovisko odborných společností k předepisování PCSK9-inhibitorů. AtheroRev 2018; 3(3): 161–168.
  52. Navarese EP, Kolodziejczak M, Schulze V et al. Effects of Proprotein Convertase Subtilisin/Kexin Type 9 Antibodies in Adults With Hypercholesterolemia: A Systematic Review and Meta-analysis. Ann Intern Med 2015; 163(1): 40–51. Dostupné z DOI: <http://dx.doi.org/10.7326/M14–2957>.
  53. Squizzato A, Suter MB, Nerone M et al. PCSK9 inhibitors for treating dyslipidemia in patients at different cardiovascular risk: a systematic review and a meta-analysis. Intern Emerg Med 2017; 12(7): 1043–1053. Dostupné z DOI: <http://dx.doi.org/10.1007/s11739–017–1708–7>.
  54. Zhang J, Tecson KM, Rocha NA et al. Usefulness of alirocumab and evolocumab for the treatment of patients with diabetic dyslipidemia. Proc (Bayl Univ Med Cent) 2018; 31(2): 180–184. Dostupné z DOI: <http://dx.doi.org/10.1080/08998280.2018.1441255>.
  55. Ray KK, Leiter LA, Müller-Wieland D et al. Alirocumab vs usual lipid-lowering care as add-on to statin therapy in individuals with type 2 diabetes and mixed dyslipidaemia: The ODYSSEY DM-DYSLIPIDEMIA randomized trial. Diabetes Obes Metab 2018; 20(6): 1479–1489. Dostupné z DOI: <http://dx.doi.org/10.1111/dom.13257>.
  56. Taskinen MR, Del Prato S, Bujas-Bobanovic M et al. Efficacy and safety of alirocumab in individuals with type 2 diabetes mellitus with or without mixed dyslipidaemia: Analysis of the ODYSSEY LONG TERM trial. Atherosclerosis 2018; 276: 124–130. Dostupné z DOI: <http://dx.doi.org/10.1016/j.atherosclerosis.2018.07.017>.
  57. Sabatine MS, Giugliano RP, Keech AC et al. [FOURIER Steering Committee and Investigators]. Evolocumab and Clinical Outcomes in Patients with Cardiovascular Disease. N Engl J Med 2017; 376(18): 1713–1722. Dostupné z DOI: <http://dx.doi.org/10.1056/NEJMoa1615664>.
  58. Ridker PM, Revkin J, Amarenco P et al. [SPIRE Cardiovascular Outcome Investigators]. Cardiovascular Efficacy and Safety of Bococizumab in High-Risk Patients. N Engl J Med 2017; 376(16): 1527–1539. Dostupné z DOI: <http://dx.doi.org/10.1056/NEJMoa1701488>.
  59. Steg PG, Bhatt DL et al. Evaluation of Cardiovascular Outcomes After an Acute Coronary Syndrome During Treatment With Alirocumab – ODYSSEY OUTCOMES. Dostupné z WWW: <https://www.acc.org/latest-in-cardiology/clinical-trials/2018/03/09/08/02/odyssey-outcomes>.
  60. Costet P. Molecular pathways and agents for lowering LDL-cholesterol in addition to statins. Pharmacol Ther 2010; 126(3): 263–278. Dostupné z DOI: <http://dx.doi.org/10.1016/j.pharmthera.2010.02.006>.
  61. Boden WE, Probstfield JL, Anderson T et al. [AIM-HIGH Investigators]. Niacin in patients with low HDL cholesterol levels receiving intensive statin therapy. N Engl J Med 2011; 365(24): 2255–2267. Dostupné z DOI: <http://dx.doi.org/10.1056/NEJMoa1107579>. Erratum in N Engl J Med 2012; 367(2): 189.
  62. Landray MJ, Haynes R, Hopewell JC et al. HPS2-THRIVE Collaborative Group. Effects of extended-release niacin with laropiprant in high-risk patients. N Engl J Med 2014; 371(3): 203–212. Dostupné z DOI: <http://dx.doi.org/10.1056/NEJMoa1300955>.
  63. Yokoyama M, Origasa H, Matsuzaki M et al. Japan EPA lipid intervention study (JELIS) Investigators. Effects of eicosapentaenoic acid on major coronary events in hypercholesterolaemic patients (JELIS): a randomised open-label, blinded endpoint analysis. Lancet 2007; 369(9567): 1090–1098. Dostupné z DOI: <http://dx.doi.org/10.1016/S0140–6736(07)60527–3>.
  64. Informace dostupné z WWW: <https://investor.amarincorp.com/news-releases/news-release-details/reduce-ittm-cardiovascular-outcomes-study-vascepar-icosapent>.
  65. Bilen O, Ballantyne CM. Bempedoic Acid (ETC-1002): an investigational Inhibitor of ATP Citrate Lyase. Curr Atheroscler Rep 2016; 18(10): 61. Dostupné z DOI: <http://dx.doi.org/10.1007/s11883–016–0611–4>.
Labels
Diabetology Endocrinology Internal medicine
A summary of the EAS consensus concerning the causal relationship between low-density lipoproteins and atherosclerotic cardiovascular diseases, prepared by the Board of the Czech Society for Atherosclerosis
Consensus statement of professional associations on prescribing of PCSK9-inhibitors
Comments on the most important and recent studies involving PCSK9i
Inflammation and atherosclerosis
Bilirubin: from an unimportant waste product to important myocardial infarction predictor
“The higher the better” seems to be no longer true for HDL-cholesterol
Current views on metabolic syndrome
Lipoprotein(a) – the cardiovascular risk factor: significance and therapeutic possibilities
Why not to interfere with LDL-cholesterol freefall and why not to talk badly about statins
PCSK9 inhibitors and diabetes mellitus
The changes in cardiovascular prevention practice between 1995–2017 in the Czech Republic: a comparison of EUROASPIRE I, II, III, IV and V study
Article was published in

Internal Medicine

Issue 12
2018 Issue 12
Most read in this issue
Topics Journals
Login
Forgotten password

Enter the email address that you registered with. We will send you instructions on how to set a new password.

Login

Don‘t have an account?  Create new account

#ADS_BOTTOM_SCRIPTS#